Key facts
- It has raised $6.6M across 2 recorded rounds; the latest was Seed Round ($2.4M) in Sep 2025.
- Mercury Bio has filed 3 Form Ds with the SEC since 2023, most recently Feb 2025 ($3K sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for Mercury Bio
Funding rounds
2 roundsAbout Mercury Bio
Developer of a biomolecular delivery platform designed to transform and treat viral diseases, cancer, and inflammatory conditions. The company's platform delivers natural-like ribonucleic acid molecules to specific cells and organs and destroys the virus, without affecting the human genes, blocking further replication and spread of the virus while enhancing the production of essential hormones such as insulin, enabling medical researchers to treat any emerging virus by silencing deleterious genes.
- Sector
- Healthcare
- HQ
- Santa Fe, NM, United States
- Founded
- 2020
- Employees
- 12
- Website
- mercurybio.com/
- Ownership
- Privately Held (backing)
Mercury Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mercury Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mercury Bio in its N-PORT filings yet. We sweep new filings monthly.